



WCN 2023
XXVI WORLD CONGRESS
OF NEUROLOGY
MONTREAL, 15-19 OCTOBER, 2023



DEMENTIA AND BEHAVIOURAL NEUROLOGY – DIAGNOSTIC CRITERIA FOR NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA

Diagnosing and Treating Agitation in Dementia

Krista L. Lanctôt, PhD

Bernick Chair in Geriatric Psychopharmacology;
Senior Scientist, Sunnybrook Research Institute;
Professor of Psychiatry and Pharmacology,
Vice Chair, Basic and Clinical Sciences, Department of Psychiatry,
University of Toronto





WCN 2023
XXVI WORLD CONGRESS
OF NEUROLOGY
 MONTREAL, 15-19 OCTOBER, 2023



√ I have a relationship with a for-profit and/or a not-for-profit organization to disclose:

| Company / Name | Honoraria / Expense | Consulting / Advisory Board | Funded Research | Royalties / Patent | Stock Options | Ownership / Equity Position | Employee | Other (specify) |
|-----------------------|---------------------|-----------------------------|-----------------|--------------------|---------------|-----------------------------|----------|-----------------|
| Biogen Inc. | | √ | | | | | | |
| BioXcel Therapeutics | | √ | | | | | | |
| Bright Minds | | √ | | | | | | |
| Bristol-Meyers Squibb | | √ | | | | | | |
| Cerevel Therapeutics | | √ | √ | | | | | |
| Eisai Co., Ltd. | | √ | | | | | | |
| Exciva GmbH | | √ | | | | | | |
| ICG Pharma | | √ | | | | | | |
| Jazz Pharmaceuticals | | √ | √ | | | | | |
| Kondor Pharma | | √ | | | | | | |
| H Lundbeck A/S | √ | √ | | | | | | |
| Merck Sharp Dohme | | √ | | | | | | |
| Novo Nordisk | √ | √ | | | | | | |



Learning objectives

- By the end of this presentation, learners will be able to describe:
 - The need for diagnostic criteria in clinical and research settings
 - The 4 criteria that define agitation in neurocognitive disorders in the 2023 diagnostic criteria (Sano et al 2023)
 - The 4 special circumstances that are now considered in the updated criteria for agitation in cognitive disorders (Sano et al 2023)
 - One example of a treatment algorithm (Cummings et al 2023)

Key messages

1

- Four key criteria define agitation in neurocognitive disorders in the updated diagnostic criteria (Sano et al 2023)

2

- Four special circumstances are now addressed in the updated diagnostic criteria for agitation in cognitive disorders (Sano et al 2023)

3

- Diagnostic criteria for agitation are useful in clinical and research settings

References

- Cummings J, Sano M, Auer S, Bergh S, Fischer CE, Gerritsen D, Grossberg G, Ismail Z, Lanctôt K, Lapid MI, Mintzer J, Palm R, Rosenberg PB, Splaine M, Zhong K, Zhu CW. [Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm.](#) Int Psychogeriatr. 2023 Mar 6:1-12. doi: 10.1017/S104161022200103X. Online ahead of print. PMID: 36876335 Review.
- Sano M, Cummings J, Auer S, Bergh S, Fischer CE, Gerritsen D, Grossberg G, Ismail Z, Lanctôt K, Lapid MI, Mintzer J, Palm R, Rosenberg PB, Splaine M, Zhong K, Zhu CW. [Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition.](#) Int Psychogeriatr. 2023 Mar 7:1-13. doi: 10.1017/S1041610222001041. Online ahead of print. PMID: 36880250 Review